![Depositphotos 63914621 l](https://d14tal8bchn59o.cloudfront.net/UYAS9-2U6yXsseXf4hw0zppSqmv6emZn-P1eDwolfUc/w:960/plain/https://02f0a56ef46d93f03c90-22ac5f107621879d5667e0d7ed595bdb.ssl.cf2.rackcdn.com/sites/43283/photos/2328992/Depositphotos_63914621_L_original.jpg)
FINE-REAL: A Non-interventional Study Providing Insights Into the Use of Finerenone in a Routine Clinical Setting. This is an observational study in people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone.
Inclusion Criteria:
Inclusion Criteria:
- Adult female or male patient (≥18 years old)
- Diagnosis of CKD associated with T2D based on assessment by physician.
- Treatment according to local marketing authorization, finerenone 20 or 10 mg.Treatment should have been started up to 8 weeks before or after the ICF is signed.
- Decision to initiate treatment with finerenone must be made before ICF is signed.
- Signed informed consent